SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ozarus is an AI-powered on-chain intelligence platform built on Solana, designed to protect traders and communities from scams, rugpulls, and high-risk tokens. The platform scans thousands of tokens daily, providing real-time risk scores, security audits, and token reliability insights. Its mission is to make Solana’s ecosystem safer, transforming trading from speculation-driven chaos into a transparent, data-backed environment.

Ozarus

Ozarus Crypto is trending as community members discuss potential breakouts and early entry points. Conversations highlight positive sentiment and strong support levels, with many watching for increased volume. The crypto is associated with other tokens like SOL, BTC, and PEPE, and is referred to as a potential "moonshot."

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

Fueled by community-driven momentum, $SLAP is trending as a viral social token born from meme hype. Community members express bullish sentiment and highlight its unique energy, pointing to real-life partnerships, sponsored athletes like Karolina Arm, and a dedicated team.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending as the community debates its future, particularly its ability to attract users and projects compared to other blockchains. Discussions include the performance of its CEO and speculation about potential ETF developments, with some suggesting the need for a new direction. Bullish sentiment persists among some, who cite Google partnerships and quantum-resistant technology as reasons for optimism.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid discussions around tariffs and trade relations, particularly with Canada, following a recent ad dispute and tariff imposition. The community is engaged in heated debates regarding the implications of these policies and the broader political landscape. Some users are focused on the stock's performance, while others are discussing political and economic issues.

Fiverr International Ltd. develops an e-commerce platform that allows people to buy and sell digital services. It operates through the following geographical segments: U.S., Europe, Asia Pacific, Rest of the World and Israel. The firm offers digital marketing, graphics and design, video and animation, writing and translation, and music and audio. The company was founded by Micha Kaufman and Shai Wininger in 2009 and is headquartered in Tel Aviv, Israel.

Fiverr International Ltd

Fiverr ($FVRR) is trending as the community discusses its potential turnaround, focusing on a double bottom technical pattern and upcoming earnings. Some investors believe that the company, despite recent challenges, is undervalued and poised for growth as rate cuts occur. Others express concerns about AI's impact on the gig economy and the company's connection to Israel.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amid community discussions about potential price movements and comparisons to other meme coins like Dogecoin and Bonk. Some users are expressing frustration with its performance, while others remain optimistic, awaiting potential catalysts or a broader altcoin season. There are also conversations around market capitalization and supply.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

VIR is trending due to institutional investment updates and upcoming presentations regarding its Hepatitis Delta clinical results. Community discussions revolve around Softbank's share disposals and potential market manipulation, alongside long-term prospects related to HIV antibody development and cancer therapies. Recent analyst ratings and the initiation of Phase 3 trials are also contributing to the stock's visibility.

Skywater Technology, Inc. is a holding company. It engages in the provision of semiconductor development, manufacturing services, and packaging services. The company was founded on October 3, 2016 and is headquartered in Bloomington, MN.

SkyWater Technology Inc

SkyWater Technology is trending as investors discuss its potential in quantum computing and domestic semiconductor manufacturing, especially given its connections to D-Wave ($QBTS) and PsiQuantum, which has ties to $NVDA. Community members are highlighting SKYT's role in enabling quantum advancements and its undervalued status compared to its peers. Additionally, the potential impact of government initiatives and tariffs favoring US-based chip production is being discussed as a possible catalyst.

Plasma is the layer 1 blockchain building the stablecoin infrastructure for a new global financial system.   It is purpose-built for global stablecoin payments, offering zero-fee USD₮ transfers and custom gas tokens to help realise the stablecoin promise of permissionless access to financial services for everyone, everywhere.   Plasma’s global payments coverage and inbound suite of products position it as the native chain for stablecoin payments.

Plasma

Plasma (XPL) is trending amid discussions about its recent listing on a Chinese exchange and potential benefits from the Fed's stablecoin initiatives, with some community members anticipating a pump. However, others are expressing concerns about a recent price drop and potential market manipulation. The project's utility in enabling stablecoin payments on the Bitcoin blockchain and connections to key players like Tether are also being highlighted.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Biogen ($BIIB) is trending as community members discuss its C5aR licensing deal with Vanqua Bio, which is seen as a validation of InflaRx's ($IFRX) approach and a potential catalyst for re-evaluation in the oral complement inhibitor space; some analysts suggest Biogen's move has set a valuation benchmark, while others question the company's strategy. The community also notes Biogen's recent receipt of EU approval for Zurzuvae and an FDA roadblock for Spinraza, creating mixed sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul><li>The company said that treatment-related adverse events were observed in the study for the first few doses but ceased with continuous dosing.</li><li>The Data Monitoring Committee found no convincing evidence that the serious adverse event is related to ARCT-032 and approved the study to proceed. &nbsp;</li></ul>Arcturus Therapeutics Holdings (ARCT) on Wednesday announced interim results from a mid-stage trial of its ARCT-032 therapy in people with cystic fibrosis.In a cohort of the study, six patients with cystic fibrosis received inhaled 10 mg doses of ARCT-032 daily over 28 days.<h2 class="st-heading-2">What’s Driving Down The Stock?</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-provides-interim-phase-2-data-cystic">reported</a> that treatment-related adverse events were observed in the study during the initial doses but ceased with continuous dosing.However, the Data Monitoring Committee found no convincing evidence that the serious adverse event is related to ARCT-032 and approved the study to proceed, the company said. One treatment-related adverse event also occurred in a participant after the end of the dosing period, it said. Furthermore, the treatment was generally safe and well-tolerated, the company added.However, shares of the company fell 58% on Wednesday. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARCT">ARCT stock</a> rose from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<h2 class="st-heading-2">What Are The Firm’s Plans Ahead?</h2>Arcturus noted on Wednesday that an expanded third cohort is ongoing. The company aims to enroll up to six subjects in the cohort if there is a dose escalation response at 15 mg and if ARCT-032 continues to be generally safe and well-tolerated.The company also said that it intends to kickstart a 12-week safety and preliminary efficacy study in up to 20 cystic fibrosis participants in the first half of 2026.Cystic fibrosis (CF) is an inherited genetic disorder that causes thick, sticky mucus to build up in the body's organs, primarily affecting the lungs and pancreas. It is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.<blockquote>“We are particularly encouraged by the early signals of mucus plug reduction in Class I CF participants treated with ARCT-032 because Class I CF individuals do not produce CFTR and therefore do not respond to available CFTR modulator therapy.”— Juergen Froehlich, Chief Medical Officer, Arcturus</blockquote>ARCT stock is down 43% this year and 51% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-to-recall-nearly-13000-vehicles-in-us/cLG57HOR3q4">Tesla To Recall Nearly 13,000 Vehicles In US, But Retail Has Its Eyes Set On Q3 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medical syringe is seen with Arcturus Therapeutics company logo displayed on a screen in the background in this illustration photo taken in Poland on June 16, 2020. (Photo Illustration by Jakub Porzycki/NurPhoto via Getty Images)

Arcturus Therapeutics Stock Plunges Over 58% Today: What’s Causing The Sell-Off?

The company said that treatment-related adverse events were observed in the study for the first few doses but ceased with continuous dosing.

Equity

Zacks.com featured highlights include Flux Power, Aura Minerals, Arcturus Therapeutics and Sterling Infrastructure

Flux Power, Aura Minerals, Arcturus Therapeutics, and Sterling Infrastructure show strong price momentum amid market uncertainty.

Arcturus Therapeutics (ARCT) Moves 7.7% Higher: Will This Strength Last?

Arcturus Therapeutics (ARCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

4 Stocks With Recent Price Strength to Maximize Your Gains

FLUX, AUGO, ARCT and STRL are showing notable price strength amid a volatile market.

Are Medical Stocks Lagging  Aquestive Therapeutics (AQST) This Year?

Here is how Aquestive Therapeutics (AQST) and Arcturus Therapeutics (ARCT) have performed compared to their sector so far this year.

Arcturus Therapeutics (ARCT) is on the Move, Here's Why the Trend Could be Sustainable 

Arcturus Therapeutics (ARCT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?

Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Arcturus Therapeutics (ARCT) Surges 8.7%: Is This an Indication of Further Gains?

Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Should You Buy Arcturus Therapeutics (ARCT) After Golden Cross?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +69.37% and +20.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$11.22
Prev Close	$12.00
Open	$12.00
Dividend Yield	0.00%
50-Day Moving Average	$18.77
Beta	1.61
Avg. Volume	654,047.71
PE Ratio	-5.04

52-Week High	$24.17
52-Week Low	$8.04
Market Capitalization	$304.67M
EPS (Annual)	-$3.00
Price to Book	1.32
Revenue Per Employee	$786,301.14
Enterprise Value/EBITDA	N/A

ARCT
Arcturus Therapeutics Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARCT News

ARCTArcturus Therapeutics Holdings Inc